Page History
The COVID-19 vaccination report has two tabs, one showing the general population and the other the at risk Vaccination report shows the vaccination status of the general population at your practice.
...
In the 'General' tab all patients are shown in a doughnut chart with the following disaggregation:
- Dose 2 Astrazeneca - second dose received
- Dose 2 Pfizer - second dose received
- Dose 2 Unknown - second dose received
- Dose 1 Astrazeneca - first dose received
- Dose 1 Pfizer - first dose received
- Dose 1 Unknown - first dose received
- Declined - currently only available in Medical Director
- Not Recorded - no vaccination recorded
At Risk Tab
The 'At Risk' tab shows a bar chart with high risk and moderate risk patients. The risk is based on the following criteria as defined by the Department of Health:
| Warning |
|---|
While we have mapped a very large number of conditions to identify all at risk patients, due to time constraints and inconsistencies between the different clinical systems, some conditions were not included. These are:
Please exercise your discretion as clinicians to ensure that all patients who are at risk are included in the vaccine allocation, as Pen CS can only provide a report that shows potentially at risk patients to the best of our ability. Also note that the high/moderate risk criteria are not aligned with the roll-out schedule, as indigenous patients over 55 are not listed as high or moderate risk. To identify those patients for the 1b phase of the roll-out please use this recipe: COVID-19 Vaccine 1b: Identify Indigenous patients over 55 Once in phase 2a, these recipes will enable you to find remaining indigenous and other patients for that phase of the rollout: |
Who is at high risk of severe illness
- are 70 years of age or over
- have had an organ transplant and are on immune suppressive therapy
- have had a bone marrow transplant in the last 24 months
- are on immune suppressive therapy for graft versus host disease
- have blood cancer eg leukaemia, lymphoma or myelodysplastic syndrome (diagnosed within the last 5 years)
- are having chemotherapy or radiotherapy.
Who is at moderate risk of severe illness
- chronic renal (kidney) failure
- heart disease (coronary heart disease or failure)
- chronic lung disease (excludes mild or moderate asthma)
- a non-haematological cancer (diagnosed in the last 12 months)
- diabetes
- severe obesity with a BMI ≥ 40 kg/m2
- chronic liver disease
- some neurological conditions (stroke, dementia, other) (speak to your doctor about your risk)
- other primary or acquired immunodeficiency (speak to your doctor about your risk)
n the 'At Risk' tab all patients are shown in a bar chart with the following disaggregation:
- High Risk
- Moderate Risk
Each bar has further information about the patients showing:
- Dose 2 Astrazeneca - second dose received
- Dose 2 Pfizer - second dose received
- Dose 2 Unknown - second dose received
- Dose 1 Astrazeneca - first dose received
- Dose 1 Pfizer - first dose received
- Dose 1 Unknown - first dose received
- Declined - currently only available in Medical Director
- Not Recorded - no vaccination recorded
- Dose 1 Categories
- Dose 1 Astrazeneca (Vaxzevria)
- Dose 1 Pfizer (Comirnaty)
- Dose 1 Moderna (Spikevax)
- Dose 1 Unknown
- Dose 2 Categories
- Dose 2 Astrazeneca (Vaxzevria)
- Dose 2 Pfizer (Comirnaty)
- Dose 2 Moderna (Spikevax)
- Dose 2 Unknown
- Declined
- Not Recorded
Below are the inclusion criteria for each category,
- Dose 1 Categories include patient population who have had received at least one dose
- Dose 2 Categories include patient population who are fully vaccinated (received both doses).
- For Declined category includes patients who declined the vaccination. This feature is currently available for Medical Director CIS only.
Footnote: COVID-19 Vaccine eligibility/choice is at the discretion of the service provider and participants. Please check the Department of Health current guidelines at https://www.health.gov.au/
The Patient Reidentification report shows details on the dose and the diagnosis relevant for the high or moderate risk status:
